Conformal Prediction and Venn-ABERS Calibration for Reliable Machine Learning-Based Prediction of Bacterial Infection Focus

Jacob Bahnsen Schmidt[*1, 2], Karen Leth Nielsen[1], Dmytro Strunin[1], Nikolai Søren Kirkby[1], Jesper Qvist Thomassen[3], Steen Christian Rasmussen[1], Ruth Frikke-Schmidt[3, 4], Frederik Boëtius Hertz[1, 5], Allan Peter Engsig-Karup[2]

[1]Department of Clinical Microbiology, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Region Hovedstaden, Denmark

[2]Department of Applied Mathematics and Computer Science, Technical University of Denmark, Asmussens Allé, 303B, Lyngby, 2800, Region Hovedstaden, Denmark

[3]Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Region Hovedstaden, Denmark

[4]Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen, 2200, Region Hovedstaden, Denmark

[5]Department of Immunology & Microbiology, University of Copenhagen, Blegdamsvej 3B, Copenhagen, 2200, Region Hovedstaden, Denmark

Corresponding author:

Jacob Bahnsen Schmidt

Department of Clinical Microbiology 7602, Rigshospitalet

Ole Maaløes vej 26; DK-2200 Copenhagen N; Denmark

E-mail: Jacob.bahnsen.schmidt@regionh.dk

Phone: (+45) 21 14 08 48

Abstract

Finding the focus of bacterial infections can be challenging, especially for hospitalised patients. Conventional microbiological diagnostic methods are either time consuming, expensive, or difficult to interpret due to contamination. The aim of this study was to apply machine learning (ML) to reliably predict the focus of bacterial infections. This study utilised a dataset including samples from 10,153 patients, collected from November 1, 2019 to June 3, 2023 at Rigshospitalet, Denmark. The dataset contains microbiological findings, biochemical data, and vital parameters. The dataset was analysed using ML. The ML-outputs were calibrated using Venn-ABERS calibration and model uncertainty was addressed using conformal risk control. The best performing model was the XGBoost model achieving an AUC of 0.93 ± 0.051 (mean $\pm$ SD.). Combining the model with methods from the conformal prediction framework achieves predictive capabilities that surpasses similar studies, while also accounting for model uncertainty by providing statistically robust uncertainty estimates.

1. Introduction

The global mortality rate from bacterial infections remains alarmingly high. A study estimated that 7.7 million deaths worldwide in 2019 were caused by 33 different genera and species of bacteria[1]. The mortality rate associated with these infections was 52.2 deaths per 100,000 population in high-income countries. Many of these deaths are due to delayed antibiotic therapy or inadequate treatment of infections, in many cases due to resistance of the causative bacteria[2].

Clinical microbiological diagnostics provide clinicians with important information, such as the identity of the pathogen and its antimicrobial resistance profile for the treatment of infectious diseases. Today's microbiological diagnostics primarily rely on phenotypic testing, which can be slow and time-consuming due to the need for bacterial growth[3,4]. This delay in diagnosis often leads to the use of broad-spectrum antibiotics. However, narrow-spectrum antibiotics are usually more effective against specific types of bacteria and have fewer side effects compared to broad-spectrum antibiotics[3]. Ensuring that the most effective antibiotics are administered as early as possible, which in turn improves patient outcomes and ultimately lowers the global mortality rate from bacterial infections.

Furthermore, reducing the unnecessary use of antibiotics and allowing for a faster transition from broad-spectrum antibiotics to narrow-spectrum antibiotics helps mitigate the emergence of multi-drug resistance and preserve the effectiveness of existing antibiotics. In addition to the early and accurate identification of the bacterial pathogen and its antimicrobial resistance profile, it is crucial to determine whether the isolated pathogen is truly causing the disease or is merely a contaminant from the clinical specimen. Clinicians must assess patient history, vital parameters and laboratory test results to decide if the patient has an infection or is at risk for developing severe infections before administering antibiotics. If treatment is necessary, they must decide which antibiotic to use, whether it should be given orally or intravenously, and the appropriate dosage. Not only the identity of the pathogen and its resistance profile, but also the severity of the disease and the site of infection significantly influences the selection, effectiveness, and management of antibiotic therapy. Consequently, making treatment decisions and choosing the appropriate antibiotic can be complex, requiring clinical expertise and additional laboratory or imaging information. Recent antibiotic stewardship initiatives, such as the "Start smart then focus toolkit" from (www.gov.uk) attempt to guide clinicians in rational antibiotic use. Machine learning (ML) could be a valuable predictive tool, providing diagnosticians with decision support in the early stages of diagnosing bacterial infections.

Previous studies have shown promising results in predicting bacterial infections using data-driven ML approaches. A study by Marandi et al.[5] focused on predicting bloodstream infection (BSI) primarily based on biochemical data. Their best performing model, LightGBM, achieved an AUC of 0.69, with a sensitivity of 0.57 and specificity of 0.70. Rawson et al.[6] used support vector machines (SVM) to predict the onset of community-acquired bacterial infections within the first 72 hours of hospital admission. Using six commonly available blood parameters, they achieved an AUC of 0.84, with a sensitivity of 0.89 and specificity of 0.63 at a likelihood cut-off of 0.81. Slightly adjusting the cut-off to 0.82 resulted in a

sensitivity of 0.44 and specificity of 0.93, indicating potential model uncertainty
and calibration issues.

In this study, we aimed to develop a novel data-driven approach using the
conformal prediction framework[7], to create a reliable, fast and cost-effective ML
approach for supporting clinicians and diagnosticians in diagnosing bacterial
infections. This method addresses known issues related to model uncertainty in
the field of machine learning, providing more robust and interpretable
predictions. By leveraging electronic health records and biochemical data, our
goal was to create a foundation for a future ML model that, by utilizing the
conformal prediction framework, can offer accurate predictions with well-
calibrated confidence levels, ultimately enhancing decision-making in clinical
settings and improving patient outcomes.

2. Methods

2.1. Data Collection
This study utilised a retrospective cohort design, including patients of all age
groups who had positive bacterial cultures sampled at Rigshospitalet
(Copenhagen, Denmark) between November 1, 2019 and June 3, 2023.

With 1,300 beds, Rigshospitalet serves as a tertiary hospital primarily for referral
and highly specialised treatment. The dataset was produced using Danish
electronic health records, i.e., patient journals, by combining data from the
electronic patient journals (Sundhedsplatformen, Epic Systems Corporation) and
the MADS database (Department of Microbiology Data Systems, in Danish
Mikrobiologisk Afdelings Data System). Doublets, defined as subsequent isolates
stemming from the same patient with the same outcome within 30 days, were
removed from the dataset.

Biochemical test results from blood samples and vital parameters were gathered
up to seven days prior to the positive conventional cultures. The biochemical test
results and vital parameters were aggregated using the mean on each day per
patient. This resulted in a dataset consisting of 73 features (Table 1). 58
describing the patient's biochemical test results, ten describing the patient's vital
parameters, two describing the patient's age and sex, and three features gained
from feature engineering. Furthermore, data transformations were applied to
each feature to obtain Gaussian distributed features, as described in S6. For the
purpose of supervised machine learning (ML), the dataset was labelled using a
table describing the findings related to the bacterial isolates. Specifically, ML
labels were generated using a combination of the sample origin and type of
bacteria found in the sample (S14 shows the ML-label assigned to each
combination of bacteria and origin).

The labels in this study included three foci of infection: airway infections
(airways), blood stream infections (BSI), urine tract infections (UTI). For each
focus of infection, we categorized bacteria into two groups: (1) typical pathogens
(hereafter referred to as "pathogens") and (2) organisms that are usually not
pathogens or are common contaminants (hereafter referred to as "PS thus PSBSI,
PSUTI, PSairways"). This classification was based on recent publications, adjusted

| 131 | to local guidelines, and considered the setting of a referral hospital. We used the |
| 132 | following sources to inform our categorization[8–10]. |

133	This approach allowed us to differentiate between organisms likely to cause true
134	infections and those more likely to represent contamination or colonization in this
135	specific context.

136	Due to the species included for sequencing, the class PSBSI was excluded from the
137	analysis as this class only included 11 positive blood samples. Figure 1 provides
138	an overview of the study design.

Figure 1 Overview of the Machine Learning pipeline used in this study from data collection to model evaluation.

2.2. Machine Learning

The dataset includes patients with a positive bacterial culture isolated from a wide range of body sites. The ML problem was framed as a seven dimensional one-vs-rest binary classification task. The goal was to create a model that could distinguish between seven different classes (different foci of infections and colonizations), each of them treated separately in a one-vs-rest approach, where the model learns to identify a particular focus of infection/colonization (the "one") and distinguish it from the combined group of the remaining foci of infection/colonization (the "rest"). The ML-models were evaluated using 5-fold cross-validation, with an 80-20% split between training and test sets.

This study tested the use of a Support Vector Machine[11] (SVM) and a Gradient Boosting Machine (GBM). These were implemented using Scikit-learn version 1.3.2 and python 3.8 - AzureML. Additionally, the XGBoost classifier[12] version 1.3.3 was used, which is a scalable tree boosting algorithm building on the ideas of Friedman 2001[13]. XGBoost is an ensemble method that utilises a forest of simple classification trees. And can handle missing data, so no further preprocessing was necessary when training the XGBoost model. The model was optimised using a narrow grid search and the optimal hyperparameters was found to be the default settings of the XGBoost model (for information on the SVM setup see S3).

Generally, ML-methods struggle with addressing model uncertainty. To tackle this issue, this study employed methods from the conformal prediction framework[7,14], using a calibration dataset of 1000 observations. First the probabilistic model outputs were calibrated using the Venn-ABERS (VA) calibration technique[15]. VA calibration aims to adjust the probabilistic model outputs, to better match the ground truth.

In other words, if the model outputs a 42% probability of airway infection, this should accurately reflect the real-world likelihood. VA calibration uses a two-fold isotonic regression: one describes the probability of belonging to the class, and the other describes the probability of not belonging to the class. These regression models create a prediction interval (p_0, p_1) for an observation belonging to the positive class, with a guarantee that the true probability lies within this interval[16]. The adjusted probability outputs are calculated using the two isotonic regression models [17] and the formula in Eq. (1).

$$p = \frac{p_1}{1 - p_0 + p_1} \qquad \text{Eq. (1)}$$

In practice, it is desirable to produce a model that can provide uncertainty guaranties. Therefore, this study employed the Conformal Risk Control (CRC) procedure from the conformal prediction framework[18]. CRC is a technique used to ensure reliable predictions that contain most of the true labels, while maintaining a user-specified error rate. In other words, CRC aims at creating prediction sets that are both accurate and meaningful.

The intuition behind CRC can be described in a handful of steps[14,18]. First the user chooses an acceptable error rate called α. This should be thought of as the maximum error rate that the user can tolerate to accept the ML prediction in a

given application. Secondly, prediction sets for new observations are generated, ideally including the true labels of the observations. The third step is the balancing act, which ensures that the average error of the prediction sets, generated by a suitably chosen loss function is less than or equal to the chosen error rate. In the context of multi-label classification, as in this study, where each patient can have multiple focuses of infection, the goal is to produce a classifier that can assign accurate probabilities to each focus of infection and then choose thresholds, such that only predictions or focuses of infection with adequately high probability scores are included in the prediction set. This is an important part of the CRC procedure and essentially helps keeping the prediction sets small and meaningful, such that only the most likely outcomes are included in the prediction set.

Intuitively this also means that the size of the prediction sets wary with the difficulty of the new observation. If a new observation is diagnostically easy, then the resulting prediction sets will be small. However, if a new observation is difficult, then the prediction sets will be comparatively larger. Put differently, the model signals uncertainty in a human like fashion by generating prediction sets of different sizes based on how certain the model is.

This study used the False negative rate (FNR) as the loss function, to control the sensitivity, setting the user specified error rate $\alpha = 0.1$, which essentially ensures a sensitivity of at least 90% on average. For a more thorough and technical description of the mathematical implementation of CRC see S4.

This study has also assumed a random pool based active learning[19] (AL) strategy for the sampling in order to estimate how much data is required to train similar models in the future.

We also performed a sensitivity analysis, removing all hematopoietic patients and patients with ($LEU < 1 \cdot 10^9/L$) from the dataset. A low leucocyte count may associate with increased risk of BSI, especially among patients with cancer or hematopoietic stem cell transplantation recipients and the presence of this population in our dataset may impact the model.

2.3. Model Evaluation

The models were evaluated using area under the receiver operating characteristics curve (AUC), as well as precision, sensitivity, specificity, F1-score, and multi class Brier score. Finally, this study examined the best performing model using Shapley additive explanations (SHAP). SHAP is a model agnostic tool that uses game theory to interpret the output of machine learning models[20], that can be used with caution for interpretability[21].

3. Results

This study included 10,153 hospitalized patients from both sexes and all age groups and from whom a bacterial isolate was recovered and processed at the Department of Clinical Microbiology (DCM) at Rigshospitalet between November 2019 and June 2023. From these 10,153 patients, 20,037 positive bacterial isolates of a diverse array of species (listed in S14) were processed at the DCM (on average 1.97 isolates per patient) and paired with 30,123 sets of biochemical test results. From these biochemical test results, 6,138 were related to isolates from

| 228 | the respiratory tract, 2,968 related to the blood stream, 13,052 related to the |
| 229 | urinary tract and 9,922 related to other body sites. |

The patients were categorized into groups based on the sample site of the clinical
isolate. The first group comprised patients with a clinically apparent infection of
the respiratory tract (1,228), the second with a blood stream infection (2,968) and
the third with a urinary tract infection (11,430). There were 55 patients who were
categorized as having a UTI as well as a respiratory tract infection, 364 patients
were categorized with both a BSI and a UTI and 28 patients with simultaneous BSI
and respiratory tract infection.

There were also patients from whom bacterial organisms that are usually not
pathogens or are common contaminant were recovered from the respiratory tract

Infection focus	Number of Observations	% of samples
Airway	1,228	4.08
PSAirway	4,910	16.30
BSI	2,968	9.85
UTI	11,430	37.94
PSUTI	1,622	5.38
Other	9,922	32.94

(a)　　　　　　　　　　　　　　　　　　　　**(b)**

Figure 2(a) shows an overview of the dataset, as an Euler diagram, where each ellipse represents an infection focus. The Euler diagram does not show all intersections between infection focuses, but rather the most important ones based on correlation between groups. The Euler diagram is fitted to the dataset using the eulerr R library. Figure 2(b) shows a summary of the dataset, showing the number of observations in each infection category. Airway includes airway infections, BSI is blood stream infections, UTI is urine tract infections, Other is an ensemble of other types of infection. PS denotes organisms that are usually not pathogens and common contaminants. This term is used to define observations that potentially could be contamination rather than infection. It should also be noted that the column % of samples sum to more than 100%, as patients can have multiple focuses of infection.

(4,910), the urinary tract (1,622) or the blood stream (11). These patients were
categorized into the three patient groups of airway, urinary tract and blood
stream contamination / colonization. The group of BSI contaminations was
however removed due to data sparsity. An overview of the patient group sizes is
outlined in Figure 2, as an Euler diagram and a table, describing both the absolute
number and overlaps in each of the 6 resulting infection classes.

In the next step, 73 features were used as input for a model to predict the patient's
site of infection (respiratory tract, bloodstream, or urinary tract). These features
included 58 biochemical test results, ten vital parameters, age, sex, and three
features obtained through feature engineering (Table 1).

Table 1 Table of summary statistics (Median, [IQR] and number of observations) grouped by the infection type (For binary variables only the number of observations is given). Variable describes the name of the feature in the dataset and description is a short description of the feature. Airway is airway infections; BSI is blood stream infections; and UTI is urinary tract infections. A full table describing all the variables in all infection focuses is available in S15.

Variable	Description	Unit	Airways	BSI	UTI
Sex	Patient sex	Binary	Male 779 Female 449	Male 1774 Female 1194	Male 4069 Female 4069
Age	Patient age	Years	59 [44.00, 69.00] 1228	62 [42.00, 71.00] 2968	67 [53.00, 76.00] 11430
ALB	Albumin	g/L	26 [21.00, 32.00] 700	26.5 [22.00, 31.00] 1405	31 [26.00, 36.00] 6517
BASO	Basophilocyte count	10^9/L	0.03 [0.01, 0.06] 510	0.03 [0.01, 0.05] 911	0.03 [0.01, 0.06] 5711
BILI	Bilirubin	µmol/L	10 [6.00, 20.00] 563	12 [7.00, 23.61] 1499	8 [5.00, 14.00] 3915
BILIKON	Conjugated bilirubin	µmol/L	101 [8.10, 194.75] 4	13.5 [9.00, 18.75] 30	2 [2.00, 5.25] 104
CARB	Carbamide	mmol/L	8.5 [5.50, 14.00] 947	8.95 [5.70, 15.30] 1499	6.9 [4.50, 11.10] 5925
CREA	Creatinine	µmol/L	81 [55.50, 128.50] 1157	82 [58.00, 136.00] 2689	72 [54.00, 107.00] 10415
CRP	C-reactive protein	mg/L	57 [17.00, 139.00] 1165	45 [11.00, 116.88] 2602	21 [6.00, 58.00] 9505
DiastolicBP	Diastolic blood pressure	mmHg	60.41 [54.57, 68.82] 1149	66.5 [57.39, 75.00] 2698	68.83 [60.58, 77.75] 9999
EWS	Early warning score	Integer	2.67 [1.00, 4.36] 342	1.33 [0.50, 3.00] 1789	1 [0.00, 2.00] 7231
HB	Hemoglobin	mmol/L	6.2 [5.40, 7.20] 1201	6.1 [5.40, 7.05] 2833	6.9 [5.90, 7.90] 10939
HDL	High density lipoprotein	mmol/L	1.02 [0.85, 1.40] 28	1.01 [0.67, 1.35] 70	1.31 [1.04, 1.67] 972
HR	Heart rate	min^{-1}	88 [77.01, 100.54] 1178	89.5 [78.50, 101.87] 2741	81.73 [71.50, 93.50] 10145
LDH	Lactate dehydrogenase	U/L	295 [205.00, 452.00] 625	240 [182.00, 359.00] 1233	221 [182.00, 286.00] 4010
LEU	Leukocyte count	10^9/L	10.9 [7.60, 14.83] 1176	8.5 [4.10, 13.00] 2690	9.1 [6.70, 12.30] 9946
LYMFO	Lymphocyte count	10^9/L	1.23 [0.71, 1.81] 509	0.95 [0.51, 1.50] 910	1.37 [0.93, 1.91] 5712

Variable	Description	Unit	Airways	BSI	UTI
NEUTRO	Neutrophil count	10⁹/L	7.9 [5.47, 11.00] 495	7.13 [4.31, 11.00] 889	6.42 [4.48, 9.14] 5573
O2Therapy	Oxygen therapy	L/min	35.15 [3.50, 50.87] 1113	0 [0.00, 25.86] 2104	0 [0.00, 2.67] 7918
PROCAL	Procalcitonin	µg/L	0.66 [0.22, 2.59] 247	0.81 [0.27, 2.94] 243	0.29 [0.10, 0.69] 344
Saturation	Oxygen saturation	%	96.37 [94.72, 97.80] 1171	97.5 [96.17, 99.00] 2631	97.5 [96.00, 98.67] 9745
SystolicBP	Systolic blood pressure	mmHg	119.32 [106.00, 132.82] 1158	122 [107.33, 136.50] 2717	128.87 [115.25, 143.92] 10028
Temperature	Body temperature	°C	37.15 [36.66, 37.64] 1145	37.1 [36.60, 37.75] 2650	36.95 [36.55, 37.41] 9624
eGFR	Estimated Glomerular Filtration Rate	mL/min	77 [45.00, 90.00] 1061	71 [38.00, 90.00] 2452	80 [50.00, 90.00] 9870
Weight	Weight	kg	80 [63.88, 95.00] 599	72.8 [57.50, 86.60] 1329	71.33 [58.57, 84.25] 4555

An overview of the model performance is presented in Table 2. The XGBoost model achieved the highest AUC (mean ± std.) of 0.93 ± 0.051, outperforming the SVM on nearly all performance metrics. The sensitivity of the naïve XGBoost model was 0.63 ± 0.101 (mean ± std.), meaning it correctly predicted the label in 63% of the positive cases. The precision of the XGBoost model was 0.83 ± 0.094, indicating that if the model makes ten predictions, roughly eight will be correct. Additionally, the XGBoost model had a lower multi-class Brier score of 0.389, suggesting better calibration. Applying the VA calibration substantially improved the F1-score for both models, indicating a better overall balance between precision and sensitivity. Using the CRC method achieved the desired sensitivity of at least 90%, but this increased sensitivity came with a trade-off in precision and specificity.

Model	PPV	SEN	SPC	F1	MBS	AUC	CPU TT
Naive SVM	0.84 (0.045)	0.37 (0.035)	0.94 (0.008)	0.46 (0.044)	0.523 (0.053)	0.87 (0.045)	9.92 (20.53)
VA SVM	0.73 (0.045)	0.57 (0.092)	0.90 (0.007)	0.63 (0.080)	0.492 (0.068)	..	..
CRC-VA SVM	0.44 (0.036)	0.90 (0.015)	0.58 (0.074)	0.57 (0.034)	..	..	..
Naive XGB	0.83 (0.094)	0.63 (0.101)	0.94 (0.022)	0.67 (0.247)	0.389 (0.103)	0.93 (0.051)	1.48 (1.73)
VA XGB	0.79 (0.088)	0.70 (0.127)	0.92 (0.020)	0.74 (0.117)	0.366 (0.114)	..	..
CRC-VA XGB	0.61 (0.100)	0.90 (0.013)	0.78 (0.121)	0.71 (0.087)	..	..	..

The improved performance with VA calibration is also evident from the calibration curves in Figure 3. When the naïve XGBoost model predicts a 60% chance of infection for any infection site, the actual probability is closer to ∼ 70-90%. Applying VA calibration results in a better-calibrated model, where a predicted probability of 60% corresponds to an observed probability of around 50-70%.

(a)

(b)

Figure 3 (a) Naïve XGBoost (b) VA calibrated XGBoost. Micro averaged calibration curves for the XGBoost model, showing the mean predicted probability vs. the fraction of positives. The blue lines represent airway infections (airways) and common contaminants of the airways (PSairways). The red line represents blood stream infections (BSI). The yellow lines represent urinary tract infections (UTI) and common contaminants of the urinary tract (PSUTI). The green line represents other types of infection (Other).

(a)

(b)　　　　　　　　**(c)**　　　　　　　　**(d)**

Figure 4 Overview of the XGBoost model performance on the test sets. (a) receiver operating characteristics (ROC) for each infection class using 5-fold cross validation. (b), (c), (d) Confusion matrices for the XGBoost model in its naïve, VA calibrated, and CRC-VA calibrated form respectively. The confusion matrices are summed across the 5-fold cross validation (for reference a theoretically perfect confusion matrix can be seen in S8). VA: Venn-ABERS, CRC: conformal risk control, Airways: airway infections, BSI: blood stream infection, UTI: urine tract infection, PS: organisms that are usually not pathogens and common contaminants, AUC: area under the ROC curve.

Figure 4a illustrates the receiver operating characteristics (ROC) curve of the best
performing model (XGBoost) based on AUC, multi class Brier Score, and F1-score.
The model generally shows strong performance in predicting the patients' site of
infection, with the highest AUC observed for predicting airway infections and
urine contamination, while the lowest AUC is seen in the "Other infections" class.
Figure 4b-d depicts the confusion matrices for the XGBoost model in its naïve, VA
calibrated, and CRC-VA calibrated states. It is evident that VA calibration
substantially increases the number of true positives (TP). Controlling the
sensitivity to at least 90% on average using CRC results in an increased number
of TPs, but also increases the prediction set size, as indicated by the elevated
number of False Positives (FP).
295

Figure 5 Prediction set sizes at different levels of α when applying the conformal risk control method. α corresponds to the user specified error tolerance, from left to right the figure shows prediction set sizes at 1, 5, 10, 20 and 30% error rates.

The CRC method mathematically signals uncertainty in a manner similar to human
intuition. Figure 5 displays the prediction set sizes at different levels of α. When α
= 0.01, corresponding to a sensitivity of at least 99% on average, the model
includes a larger proportion of the label space in the prediction set. Higher levels
of α results in smaller prediction sets with a larger risk of missing the true class.
At α = 0.3 corresponding to a sensitivity of at least 70% on average, the median
prediction set size is one. It is also evident that the CRC method can produce
empty prediction sets when the predicted probability of each class is below the
probability threshold, indicating lack of confidence in predicting a class label.

Active learning (AL is a framework [19] aimed at maximising model performance
while minimizing the number of annotated samples required. Based on the
available dataset, we estimate the amount of data needed to achieve the expected
results using a pool based AL strategy. Figure 6 shows that the XGBoost model
requires approximately 2,000 positive samples per class to approach the maximal
obtainable sensitivity.

Figure 6 Sensitivity of the Naïve XGBoost model plotted vs. the number of positives in the training dataset for each infection class, when the model is trained with different training dataset sizes. Airways is airway infections, BSI is blood stream infections, UTI are urine tract infections, PS denotes organisms that are usually not pathogens and common contaminants,, and the "Other" class is an ensemble of other types of infection Similar results for other performance metrics can be seen in S7-S13.

The sensitivity analysis, removing hematopoietic patients and patients with low leucocyte count yielded similar results based on the performance metrics, only varying AUC by a few percentage points (absolute difference in AUC was 1.17 ± 1.17 pp. ± std.).

The SHAP-plots in Figure 7 illustrate feature importance across the different classes of infection. Figure 7a ranks features by their SHAP-value, highlighting their importance. It is evident that the model heavily relies on information about the patient's ability to breathe and oxygenate their blood, as O_2 therapy and blood oxygen saturation are amongst the most important features.

Figure 7c depicts the feature importance related to BSIs. The two most important features for predicting BSIs are the leukocyte (LEU) count and the hemoglobin concentration (HB). Specifically, a low LEU count corresponds to a high risk of BSI compared to all other classes of infection. While bacterial infections typically cause elevated LEU counts [22], this result may be explained by the large group of immunocompromised patients at Rigshospitalet. Furthermore, the patients' temperature appears to be a predictor of BSI. This aligns with the literature, as patients with BSI are known to have elevated body temperatures, except in cases where the blood circulation is affected, which can cause hypothermia [23].

330   Figure 7d shows that the greatest risk factor when predicting UTI is the patient
331   sex, with female encoded as zero and male as one. Furthermore, high levels of C-
332   reactive protein (CRP) correspond to a lower chance of UTI compared to the other
333   classes of infection, while a high concentration of albumin (ALB) indicates a
334   higher likelihood of predicting UTI.

Figure 7 SHAP summary plots displaying feature importance of the 9 most important features as determined by SHAP-value. The SHAP-value is equivalent to the log-odds of predicting the class. Sex is encoded categorically as, male=1, female=0. airways: airway infection, BSI: blood stream infection, UTI: urine tract infection, PS: oranisms that are usually not pathogens and common contaminants, O2Therapy: O2 Therapy, EWS: Early warning score, age: patient age in years, Saturation: blood O2 saturation percentage, LDH: lactate dehydrogenase, CREA: creatinine, eGFR: estimated glomerular filtration rate, DiastolicBP: diatolic blood pressure, LEU: leukocyte count, LYMFO: lymphocyte count, Temperature: patient body temperature, CARB: Carbamide, BILI: bilirubin, ALB: albumin, HB: hemoglobin, CRP: C-reactive protein, HR: Heart rate, SystolicBP: Systolic blood pressure, INR: International normalized ratio blood test, BASO: Basophilocyte count, GLU: Glucose, NEUTRO: Neutrophil count.

4. Discussion

The aim of this study was to develop a data-driven model that can predict the focus of infection within a reasonable margin of error. The best performing ML-model was the XGBoost model, achieving an AUC of 0.93, which is infrequently observed within the field of bacterial infections. This model also showed a good balance between sensitivity and specificity, meaning that the model performance is acceptable, both when measured on how well it predicts the correct label and how well it excludes the incorrect labels. The naïve model state did, however, prove to be badly calibrated, nevertheless using Venn-ABERS (VA) calibration and conformal risk control (CRC) a well calibrated model with a guaranteed sensitivity of at least 90% on average was obtained, meaning that in nine out of ten cases, the correct prediction is included in the prediction set, while also not creating excessively large prediction sets. Compared to similar studies in the field of bacterial infections VA-calibration and CRC results in a considerably improved model performance. Furthermore, it was found, through active learning, that studies in order to achieve satisfactory model quality should include a minimum of 1,000 positive observations pr. class and preferably 2,000 observations or more.

Adopting ML to clinical practices requires a high level of trustworthy artificial intelligence[24] (AI). In a clinical setting clinicians and diagnosticians are responsible for human lives. In order for the clinicians and diagnosticians to trust the predictions made by AI and ML-models, the models need to be built with transparency, robustness, and a high level of explainability [24]. In order to achieve this one should address known biases in the dataset, potential strengths and weaknesses of the ML-models, and provide explanations for the model outputs.

The dataset in this study comes with a handful of natural biases. The data is recorded at Rigshospitalet in Denmark. Rigshospitalet is a highly specialised tertiary hospital, patients therefore often present with numerous comorbidities. This makes diagnostics increasingly difficult in itself, but it also introduces biases towards sick people in the dataset. The ML-labels used in this study could also introduce biases. The labels are generated using the sample origin and the bacterial species. However, this combination is likely not perfectly true to reality and could potentially introduce a level of epistemic errors into the dataset. In order to increase trustworthiness and diagnostic value of the ML-models the labels should be redefined using other more strict definitions of contamination.

The findings align well with previous knowledge, expected findings and demonstrate that the ML-modelling can support identifying clinically relevant factors for predicting the different foci for bacterial infections. The ML-model's heavy reliance on O2 therapy and blood oxygen saturation for predicting respiratory infections, the identification of leukocyte count and haemoglobin concentration as important features for BSI prediction, and the identification of patient sex as the most important factor for UTI prediction is clinically sensible and consistent with epidemiological data. The inverse relationship between CRP levels and UTI prediction, as well as the positive association with albumin levels, may reflect the model's ability to distinguish UTIs from more severe systemic infections. This nuanced interpretation of biomarkers demonstrates the ML-model's sophistication in differentiating between infection types. These results are promising since the active learning framework suggests that approximately 2,000 positive samples per class are needed to achieve near-optimal model

performance. This information is valuable for future studies, as it provides a clear
guideline for dataset size requirements. It also indicates that the current study
likely had sufficient data to develop a robust model. The naïve models proved to
be badly calibrated. This issue was handled using VA-calibration. Badly calibrated
models could potentially decrease the trustworthiness of the model and ML in
general, as users empirically will start to doubt the ML-models if it consistently
outputs either lower or higher chance of bacterial infection than what the user
observes.

The usage of tools in this study are chosen with clinical application in mind.
Specifically, the usage of conformal predictions to generate statistically robust
prediction sets is of potentially high value in a clinical setting. Many ML-methods
do not provide uncertainty estimates for their predictions. Applying the
conformal risk control (CRC) method generates prediction sets of varying size as
seen in Figure 5. This is clinically useful as the framework not only provides
statistically sound uncertainty guaranties for the user specified performance
metrics, but also allows the ML-models to generate prediction sets of varying size,
which essentially signals uncertainty in a human like fashion and is known to
significantly improve accuracy in human-in-the-loop systems[25], where humans
make decisions based on expert knowledge and ML-outputs.

Prediction sets can be a great way of signalling uncertainty, but the size of the
prediction sets needs to be discussed. For example, using CRC it is possible to
guarantee a certain level of sensitivity. Controlling the sensitivity to 99% for the
XGBoost model results, by definition, in few predictions sets where the correct
label is excluded. This is however achieved by outputting half the label space for
median observations. In practice large prediction sets do not provide any direct
diagnostic value to the clinicians or diagnosticians, it does however indicate high
uncertainty, which warrants further examination of the patient. Reducing the
sensitivity to 70% mostly resulted in prediction set sizes of two or less. This size
is potentially more useful as it significantly narrows the potential search field. The
issue with this setting is that the model essentially guarantees an error rate of
approximately 30%. When using CRC in practice it is therefore important to find
the right balance between prediction set size and error rate, such that the
prediction sets are narrow enough that clinicians and diagnosticians can extract
actual value from them, but still wide enough to provide a reasonably low error
rate. Initially CRC might not seem like a powerful tool solely based on
performance metrics, however considering that CRC provides any model with
statistically robust uncertainty guaranties on the sole condition that new
observations stem from the same distribution as the one provided by the
calibration dataset, it should perhaps not only be considered a powerful tool, but
a necessity when applying ML in a health care setting.

In terms of explainability the XGBoost model has been analysed using SHAP-plots.
SHAP-plots are widely used as a tool for explainable AI. SHAP-analysis assumes
feature independence, this is almost never achievable in real life applications, and
the SHAP-analysis should therefore be interpreted with a pinch of scepticism[21].
From the SHAP-analysis it is also clear that the dataset contains human
introduced biases, as O_2 therapy is deemed as the most important feature when
predicting airway infections. This feature is controlled by the diagnosticians and
is therefore naturally biased towards the human decision maker. Nevertheless,
the majority of the features deemed important by the model are expected and

| 434 | known biomarkers of bacterial infection (age[26], LDH[27], LEU[22], temperature[23], sex, |
| 435 | and CRP). |

436	Our study has several limitations. It is a retrospective design, which may limit the
437	ability to control for confounding factors, and the model was not validated on an
438	external dataset from a different hospital or time period, which would have
439	provided stronger evidence of its generalizability. The low prevalence of positive
440	blood cultures in the dataset may affect the model's performance, particularly its
441	positive predictive value. Additionally, the model does not incorporate important
442	clinical information such as comorbidities or presence of indwelling devices,
443	which are known risk factors for bloodstream infections.

444	However, this study combines advanced machine learning techniques (XGBoost)
445	with conformal prediction methods (VA calibration and CRC) to create a more
446	reliable and interpretable model.

447	The use of CRC to generate prediction sets of varying sizes based on uncertainty
448	is a novel approach in clinical decision support, mimicking human-like signalling
449	of uncertainty and the comprehensive analysis of bacterial infections using a wide
450	range of biochemical and vital sign data is more extensive than previous studies
451	in this field.

452	The integration of trustworthy AI principles, addressing model uncertainty and
453	providing explainable results, represents a significant step towards clinical
454	application of ML in infection diagnosis. Thus, this study provides valuable
455	insights into the data requirements for developing similar models in the future,
456	which is crucial for advancing the field of ML in clinical microbiology.

5. Conclusion

458	The XGBoost model achieved high performance (AUC 0.93) in predicting the focus
459	of bacterial infections using electronic health record data and biochemical
460	markers. Venn-ABERS calibration and conformal risk control significantly
461	improved model calibration and guaranteed a sensitivity of at least 90% on
462	average. We estimate that approximately 2,000 positive samples per infection
463	class are needed to achieve optimal model performance, as determined by active
464	learning analysis. The model identified clinically relevant predictors for different
465	infection types, such as oxygen therapy for respiratory infections and leukocyte
466	count for bloodstream infections, which aligns well with clinical observations.
467	Conformal prediction methods can generate variable-size predictions sets,
468	signalling uncertainty in a human-like fashion and potentially improve clinical
469	decision-making. Despite limitations such as its retrospective design and lack of
470	external validation, this novel approach of combining XGBoost with conformal
471	prediction methods provides valuable insights into data requirements and
472	methodological approaches for developing trustworthy AI systems in clinical
473	microbiology. These findings may have significant implications for improving
474	antibiotic stewardship and patient outcomes in the management of bacterial
475	infections.

Author contribution

Conceptualization: Jacob Bahnsen Schmidt, Frederik Boëtius Hertz, Karen Leth Nielsen, Allan
Peter Engsig-Karup

Data curation: Jacob Bahnsen Schmidt, Dmytro Strunin, Nikolai Søren Kirkby, Steen Christian
Rasmussen

Formal analysis: Jacob Bahnsen Schmidt

Investigation: Jacob Bahnsen Schmidt

Methodology: Jacob Bahnsen Schmidt, Frederik Boëtius Hertz, Karen Leth Nielsen, Allan Peter
Engsig-Karup

Ethical approval: Frederik Boëtius Hertz.

Resources: Frederik Boëtius Hertz, Karen Leth Nielsen

Software: Jacob Bahnsen Schmidt, Dmytro Strunin

Formal analysis: Jacob Bahnsen Schmidt

Supervision: Frederik Boëtius Hertz, Karen Leth Nielsen, Allan Peter Engsig-Karup

Validation: Jacob Bahnsen Schmidt, Dmytro Strunin, Jesper Qvist Thomassen, Steen Christian
Rasmussen

Visualization: Jacob Bahnsen Schmidt

Project administration: Karen Leth Nielsen, Frederik Boëtius Hertz, Allan Peter Engsig-Karup

Writing – Original Draft Preparation: Jacob Bahnsen Schmidt, Frederik Boëtius Hertz.

Writing – Review & Editing: Jacob Bahnsen Schmidt, Frederik Boëtius Hertz, Karen Leth
Nielsen, Dmytro Strunin, Nikolai Søren Kirkby, Jesper Qvist Thomassen, Steen Christian
Rasmussen, Ruth Frikke-Schmidt, Allan Peter Engsig-Karup

Materials & Correspondence: Jacob Bahnsen Schmidt

Funding

This work was funded by Department of Clinical Microbiology, Rigshospitalet, Denmark, Beta-
Health Foundation ID:1188), Den Frie Forskningsfond (DFF) (3101-00040B), and the Novo
Nordisk Foundation (NNF Laureate Grant 18OC0033946). The funders had no role in
designing and conducting the study, analysis, and interpretation of the data, or the writing,
review, and approval of the manuscript.

Ethical approval

There were no ethical concerns for this study. This was an observational, non-intervention
study. The extraction of data from registries was approved by the local data protection agency
(Journal-nr.: R-21015888) and registered in Pactius (P-2020-743).

Data Sharing

All relevant data are within the manuscript and its Supporting Information files.
We are unable to share sensitive data instances due to compliance with the

General Data Protection Regulation (GDPR) and Danish legislation. These
regulations mandate that the privacy and confidentiality of individuals must be
protected, and sensitive data should not be made publicly available without
appropriate safeguards. Therefore, we cannot provide access to the sensitive data
instances used in this study to ensure compliance with these regulations.

Code Availability

Access to the code used for the statistical design and ML-process can be made
available on reasonable request to the authors.

Competing Interest

The authors declare no competing interests.

References

1. Ikuta, K. S. *et al.* Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis
for the Global Burden of Disease Study 2019. *The Lancet* **400**, 2221–2248 (2022).

2. Cassini, A. *et al.* Attributable deaths and disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level
modelling analysis. *Lancet Infect Dis* **19**, 56–66 (2019).

3. Melander, R. J., Zurawski, D. V & Melander, C. Narrow-spectrum antibacterial agents. *Medchemcomm* **9**,
12–21 (2018).

4. Gibson, B., Wilson, D. J., Feil, E. & Eyre-Walker, A. The distribution of bacterial doubling times in the
wild. *Proceedings of the Royal Society B* **285**, 20180789 (2018).

5. Marandi, R. Z. *et al.* Prediction of bloodstream infection using machine learning based primarily on
biochemical data. (2024).

6. Rawson, T. M. *et al.* Supervised machine learning for the prediction of infection on admission to
hospital: a prospective observational cohort study. *Journal of Antimicrobial Chemotherapy* **74**, 1108–
1115 (2019).

7. Shafer, G. & Vovk, V. A Tutorial on Conformal Prediction. *Journal of Machine Learning Research* **9**,
(2008).

8. Kouri, T. T. *et al.* The EFLM European Urinalysis Guideline 2023. *Clinical Chemistry and Laboratory*
Medicine (CCLM) **62**, 1745–1747 (2024).

9. Markussen, D. L. *et al.* Diagnostic Stewardship in Community-Acquired Pneumonia With Syndromic
Molecular Testing. *JAMA Netw Open* **7**, e240830 (2024).

10. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. *New England*
Journal of Medicine (2024) doi:10.1056/NEJMoa2404991.

11. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* **12**,
2825–2830 (2011).

12. Chen, T. & Guestrin, C. Xgboost: A scalable tree boosting system. in *Proceedings of the 22nd acm sigkdd*
international conference on knowledge discovery and data mining 785–794 (2016).

13. Friedman, J. H. Greedy function approximation: a gradient boosting machine. *Ann Stat* 1189–1232
(2001).

14. Angelopoulos, A. N. & Bates, S. A gentle introduction to conformal prediction and distribution-free
uncertainty quantification. *arXiv preprint arXiv:2107.07511* (2021).

15. Vovk, V. & Petej, I. Venn-abers predictors. *arXiv preprint arXiv:1211.0025* (2012).

16. Manokhin, V. *Practical Guide to Applied Conformal Prediction in Python*. (Packt Publishing Ltd.,
Birmingham, 2023).

17. Manokhin, V. Multi-class probabilistic classification using inductive and cross Venn–Abers predictors.
in *Proceedings of the Sixth Workshop on Conformal and Probabilistic Prediction and Applications* (eds.
Gammerman, A., Vovk, V., Luo, Z. & Papadopoulos, H.) vol. 60 228–240 (PMLR, 2017).

18. Angelopoulos, A. N., Bates, S., Fisch, A., Lei, L. & Schuster, T. Conformal risk control. *arXiv preprint*
arXiv:2208.02814 (2022).

19. Settles, B. Active learning literature survey. *Computer Sciences Technical Report 1648* (2009).

20. Lundberg, S. M. *et al.* From local explanations to global understanding with explainable AI for trees. *Nat*
Mach Intell **2**, 56–67 (2020).

21. Huang, X. & Marques-Silva, J. The Inadequacy of Shapley Values for Explainability. *arXiv preprint*
arXiv:2302.08160 (2023).

22. Honda, T., Uehara, T., Matsumoto, G., Arai, S. & Sugano, M. Neutrophil left shift and white blood cell
count as markers of bacterial infection. *Clinica Chimica Acta* **457**, 46–53 (2016).

23. Kushimoto, S. *et al.* The impact of body temperature abnormalities on the disease severity and outcome
in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. *Crit*
Care **17**, 1–9 (2013).

24. Li, B. *et al.* Trustworthy ai: From principles to practices. *ACM Comput Surv* **55**, 1–46 (2023).

25. Cresswell, J. C., Sui, Y., Kumar, B. & Vouitsis, N. Conformal Prediction Sets Improve Human Decision
Making. *arXiv preprint arXiv:2401.13744* (2024).

26. Meyer, K. C. Lung infections and aging. *Ageing Res Rev* **3**, 55–67 (2004).

27. Drent, M., Cobben, N. A., Henderson, R. F., Wouters, E. F. & van Dieijen-Visser, M. Usefulness of lactate
dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *European Respiratory*
Journal **9**, 1736–1742 (1996).

28. Madsen, H. & Thyregod, P. *Introduction to General and Generalized Linear Models*. (Chapman & Hall,
Lyngby, 2011).

Data Collection

Blood culture data: 20,037 samples.
Biochemical data: 7,066,497 Biochemical test data points.
Vital parameter data: 55,150,554 Vital parameter data points.

Selection criteria:

- All ages.

- 1 or more biochemical tests maximum 7-days prior to positive bacterial culture.

- Timeperiod: from 2019-11-01 to 2023-06-03.

Data Preparation

- Data enrichment, Data types <X or >X becomes X.
- Outlier filtration.
- 73 Total features, 58 biochemical, 10 vital parameters, 3 engineered features, Sex and Age.
- Time-frame filters.
  - Biochemical results max 7-days prior to positive bacterial culture.
  - identical infection pattern from same patient within 30-days.
- Outcome, defined by bacterial species and sample origin.
- Data Transformations.
- Data imputation feature median (only relevant for the Support Vector Machine)

Dataset

30,123 Samples

Data split

5-fold cross vaildation

| Training | Test |

Machine Learning Models

- Support Vector Machine
- Gradient Boosting Machine (XGBoost)

Model Training

Data split

Test

Calibration | Test

Model post-processing

- Venn-ABERS Calibration
- Conformal Risk Control

Model Evaluation

(a)

Infection focus	Number of Observations	% of samples
Airway	1,228	4.08
PSAirway	4,910	16.30
BSI	2,968	9.85
UTI	11,430	37.94
PSUTI	1,622	5.38
Other	9,922	32.94

(b)

(a) Naive XGBoost

(b) VA calibrated XGBoost

(a)

(b)

(c)

(d)